Hypercholesterolemia Pipeline Insight 2025

Strategic Insights -

Hypercholesterolemia is a specific type of hyperlipidemia characterized by high levels of low-density lipoprotein (LDL) cholesterol in the blood. It increases the risk of heart disease and can be inherited but is often preventable and treatable through a healthy diet, regular exercise, and medication. The Hypercholesterolemia Pipeline Insight 2025 report provides comprehensive insights into the 25+ companies and 30+ pipeline drugs in the Hypercholesterolemia pipeline landscape. The report covers the pipeline drug profiles, including clinical and nonclinical stage products, and highlights the unmet needs in the treatment of Hypercholesterolemia.

Key Takeaways:

  • Novartis Pharmaceuticals has announced a study evaluating the efficacy and safety of inclisiran sodium 300 mg as a monotherapy in comparison to ezetimibe and placebo in 350 adult participants with primary hypercholesterolemia.
  • Merck Sharp & Dohme LLC has conducted a study to evaluate the longer-term safety and efficacy of enlicitide decanoate in adults with hypercholesterolemia who completed either study MK-0616-013 (NCT05952856), study MK-0616-017 (NCT05952869), or study MK-0616-018 (NCT06450366).
  • The Hypercholesterolemia pipeline report depicts a robust space with 25+ active players working to develop 30+ pipeline therapies for Hypercholesterolemia treatment.
  • The leading Hypercholesterolemia Companies such as Merck Sharp & Dohme LLC, Arrowhead Pharmaceuticals, Vaxxinity, Inc., Akeso Biopharma, Haisco Pharmaceutical Group Co., Ltd., Verve Therapeutics, Inc., Amytrx Therapeutics, EPIC BIO, Addpharma, NewAmsterdam Pharma, LIB Therapeutics, and others.
  • The report highlights the unmet needs in the treatment of Hypercholesterolemia, including the need for more effective and safer treatments, the importance of addressing the root causes of the disease, and the need for increased awareness and education about Hypercholesterolemia.
  • The Hypercholesterolemia pipeline report provides insights into the companies that are developing therapies for the treatment of Hypercholesterolemia with aggregate therapies developed by each company for the same.
  • The report emphasizes the importance of collaborations between companies and academic institutions to advance the development of Hypercholesterolemia treatments.

Statistics:

  • 25+ companies are developing therapies for the treatment of Hypercholesterolemia.
  • 30+ pipeline therapies are being developed for Hypercholesterolemia treatment.
  • The Hypercholesterolemia pipeline report highlights the importance of addressing the unmet needs in the treatment of Hypercholesterolemia.
  • 350 adult participants are being studied in the Novartis Pharmaceuticals study evaluating the efficacy and safety of inclisiran sodium 300 mg.
  • 10-year ASCVD risk score is being used to evaluate the efficacy and safety of inclisiran sodium 300 mg.

Sources:

  • "Hypercholesterolemia Pipeline Insight, 2025" report by DelveInsight
  • Study MK-0616-013 (NCT05952856) and study MK-0616-017 (NCT05952869) by Merck Sharp & Dohme LLC
  • Study MK-0616-018 (NCT06450366) by Merck Sharp & Dohme LLC
  • FDA Approval Letter for Merck's PCSK9 Inhibitor MK-0616

Note: The statistics and key takeaways are based on the provided text and may not be exhaustive or up-to-date.